You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 108 No. 1, January 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  LABORATORY SCIENCES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Collagen Shield Heparin Delivery for Prevention of Postoperative Fibrin

Timothy G. Murray, MD; Walter H. Stern, MD; David H. Chin, MD; Elizabeth A. MacGowan-Smith

Arch Ophthalmol. 1990;108(1):104-106.


Abstract

• We studied collagen shield heparin delivery to the rabbit eye utilizing radiolabeled heparin as well as a fibrin inhibition assay. Radiolabeled heparin studies revealed significant tritium delivery to the cornea, aqueous, and iris, with only trace levels detectable for the lens, vitreous, and sclera. An aqueous fibrin inhibition assay revealed that a single collagen shield soaked in heparin achieved anterior chamber anticoagulant levels that paralleled the time course of the radiolabeled heparin delivery and resulted in fibrin inhibition during the 6-hour study period. Subconjunctival heparin injection did not alter baseline aqueous anticoagulant activity. No complications related to collagen shield heparin delivery were encountered. These studies suggest that a heparin-hydrated collagen shield may prevent postoperative fibrin formation in eyes at risk for this complication, including eyes undergoing surgery for the complications of proliferative diabetic retinopathy proliferative vitreoretinopathy, and glaucoma filtration surgery.



Author Affiliations

From the Department of Ophthalmology, University of California, San Francisco; and the Veterans Administration Medical Center, San Francisco. Dr Murray is a fellow with the Retina Service, Medical College of Wisconsin, Eye Institute, Milwaukee.


Footnotes

Accepted for publication August 3,1989.

Reprint requests to the Department of Ophthalmology, Beckman Vision Center, K-301 University of California, San Francisco, CA 94143 (Dr Stern).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Subconjunctival Carboplatin Therapy and Cryotherapy in the Treatment of Transgenic Murine Retinoblastoma
Murray et al.
Arch Ophthalmol 1997;115:1286-1290.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.